Trypsinogen in urine

Trypsinogen, trypsinogen activating peptide (TAP) and carboxypeptidase activating peptide (CAPAP)

Trypsinogen

Trypsinogen (inactive form, proenzyme of trypsin) is produced by the acinous cells of the pancreas in two isoforms – trypsinogen-1 (cathodic isoenzyme, CT) and trypsinogen-2 (anodic isoenzyme, AT ). The inflammatory process in acute pancreatitis leads to increased circulating levels, and trypsinogen-2 can be detected in both serum and urinei. Premature activation of trypsinogen in the pancreatic tissue leads to the initiation of the activation cascade, autodigestion and is an important pathogenetic factor acute pancreatitis. Immunoreactive, both forms of trypsinogen (irAT, irCT) and their ratio in serum S-irAT/S-irCT or in urine U-irAT/U-irCT can be determined in the laboratory.

Clinic

2PTN

Clinically, the level of trypsinogen-2 in the urine is most often used, values ​​of 5600–10,000 µg/l correspond to a severe, severe form of acute pancreatitis, values ​​of 130–890 µg/l then a moderate to mild form of AP. In the urine, we also determine the product of conversion of trypsinogen to active trypsin - trypsinogen activation peptide - TAP. An elevated TAP level is clinically significant for assessing the severity of acute pancreatitis, when TAP values ​​in the urine above 15 nmol/l detect moderate pancreatitis, values ​​above 40 nmol/l a severe form of the disease. The most recent studies are devoted to the determination of procarboxypeptidase B activation peptide in serum or urine. The activation peptide CAPAP is longer than other peptides released during the activation of pancreatic proenzymes, therefore it is more stable and more suitable for laboratory diagnostics. The normal serum CAPAP level by RIA is 0.8 nmol/L.

Links

References

• CARROLL, JK. Acute pancreatitis: diagnosis, prognosis, and treatment. American family physician. 2007, vol. 75, no. 10, p. 1513-20, ISSN 0002-838X (Print), 1532-0650 (Electronic). PMID: 17555143.

• SANKARALINGAM, S. Use of the urinary trypsinogen-2 dip stick test in early diagnosis of pancreatitis after endoscopic retrograde cholangiopancreatography. Surgical endoscopy. 2007, vol. 21, no. 8, p. 1312-5, ISSN 0930-2794 (Print), 1432-2218 (Electronic). PMID: 17332967.

• JANG, T. Point-of-care urine trypsinogen testing for the diagnosis of pancreatitis. Acad Emerg Med. 2007, vol. 14, no. 1, p. 29-34, ISSN 1069-6563 (Print), 1553-2712 (Electronic). PMID: 17119188.

• HILAL, MA. Carboxypeptidase-B activation peptide, a marker of pancreatic acinar injury, but not L-selectin, a marker of neutrophil activation, predicts severity of acute pancreatitis. Journal of gastroenterology and hepatology. 2007, vol. 22, no. 3, p. 349-54, ISSN 0815-9319 (Print), 1440-1746 (Electronic). PMID: 17295766.

• PETERSSON, U. Characterization of immunoreactive trypsinogen activation peptide in urine in acute pancreatitis. JOP : Journal of the pancreas. 2006, vol. 7, no. 3, p. 274-82, ISSN 1590-8577 (Electronic). PMID: 16685108.

• AL-BAHRANI, AZ. Clinical laboratory assessment of acute pancreatitis. Clin Chim Acta. 2005, vol. 362, no. 1-2, p. 26-48, ISSN 0009-8981 (Print), 1873-3492 (Electronic). PMID: 16024009.

• PAPACHRISTOU, GI. Inflammatory markers of disease severity in acute pancreatitis. Clin Lab Med. 2005, vol. 25, no. 1, p. 17-37, ISSN 0272-2712 (Print), 1557-9832 (Electronic). PMID: 15749230.

• CHEN, YT. Chen YT. Pancreas. 2005, vol. 30, no. 3, p. 243-7, ISSN 0885-3177 (Print), 1536-4828 (Electronic). PMID: 15782102.

• PEZZILLI, R. Serum trypsinogen activation peptide in the assessment of the diagnosis and severity of acute pancreatic damage: a pilot study using a new determination technique. Pancreas. 2004, vol. 29, no. 4, p. 298-305, ISSN 0885-3177 (Print), 1536-4828 (Electronic). PMID: 15502646.

• LEMPINEM,. Trypsinogen-2 and trypsinogen activation peptide (TAP) in urine of patients with acute pancreatitis. J Surg Res. 2003, vol. 111, no. 2, p. 267-73, ISSN 0022-4804 (Print), 1095-8673 (Electronic). PMID: 12850473.

• MÜLLER, CA. A study on the activation peptide released from procarboxypeptidase B (CAPAP) and anionic trypsinogen in patients with acute abdominal disorders of non-pancreatic origin. Pancreatology. 2003, vol. 3, no. 2, p. 149-55, ISSN 1424-3903 (Print), 1424-3911 (Electronic). PMID: 12748424.

• KYLÄNPÄÄ-BÄCK, ML. Comparison of urine trypsinogen-2 test strip with serum lipase in the diagnosis of acute pancreatitis. Hepatogastroenterology. 2002, vol. 49, no. 46, p. 1130-4, ISSN 0172-6390. PMID: 12143219.

• KYLÄNPÄÄ-BÄCK, ML. Trypsin-based laboratory methods and carboxypeptidase activation peptide in acute pancreatitis. JOP. 2002, vol. 3, no. 2, p. 34-48, ISSN 1590-8577 (Electronic). PMID: 11884765.

• LEMPINEM, M. Predicting the severity of acute pancreatitis by rapid measurement of trypsinogen-2 in urine. Clin Chem. 2001, vol. 47, no. 12, p. 2103-7, ISSN 0009-9147 (Print), 1530-8561 (Electronic). PMID: 11719473.

• PEZZILLI, R. Clinical usefulness of the serum carboxypeptidase B activation peptide in acute pancreatitis. JOP. 2000, vol. 1, no. 3, p. 58-68, ISSN 1590-8577 (Electronic). PMID: 11854559.

• NEOPTOLEMOS, JP. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet. 2000, vol. 355, no. 9219, p. 1955-60, ISSN 0140-6736 (Print), 1474-547X (Electronic). PMID: 10859041.

• KYLÄNPÄÄ-BÄCK, M. Reliable screening for acute pancreatitis with rapid urine trypsinogen-2 test strip. Br J Surg. 2000, vol. 87, no. 1, p. 49-52, ISSN 0007-1323 (Print), 1365-2168 (Electronic). PMID: 10606910.

• KEMPPAINEN, E. Time course profile of serum trypsinogen-2 and trypsin-2-alpha1-antitrypsin in patients with acute pancreatitis. Scand J Gastroenterol. 2000, vol. 35, no. 11, p. 1216-20, ISSN 0036-5521 (Print), 1502-7708 (Electronic). PMID: 11145296.

• PETERSSON, U. Different patterns in immunoreactive anionic and cationic trypsinogen in urine and serum in human acute pancreatitis. Int J Pancreatol. 1999, vol. 25, no. 3, p. 165-70, ISSN 0169-4197 (Print). PMID: 10453418.